Acyclovir Substitution For VZIG To Prevent Severe Chickenpox Is Topic Of Advisory Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks committee whether prevention of severe varicella zoster infection could be achieved with acyclovir or immune globulin treatment. Meanwhile, the agency is seeking to expedite approval of varicella zoster immune globulin products.
You may also be interested in...
FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
Bristol Sprycel For Gleevec-Resistant Leukemia To Get Committee Review At June ASCO Meeting
FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.
Cephalon Sparlon Additional Pre-Approval Safety Study Recommended To Assess Skin Reaction Risk
FDA’s Psychopharmacologic Drugs Advisory Committee rules safety for modafinil product in children with attention deficit/hyperactivity disorder has not been adequately demonstrated.